Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio
Executive Summary
Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.